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Novelty statement:  
 Despite the well-recognised correlation between weight gain and cardiovascular (CV) 
disease, as well as Insulin-induced weight gain, there is little direct evidence relating to 
the impact of insulin-induced weight gain on CV outcomes.  
 This study robustly investigates the impact of insulin-induced weight gain on the 5-year 
risk of CV outcome and mortality  
 Weight loss >5kg in insulin users was associated with up to 31% higher risk of a three-
point composite of mortality, non-fatal acute myocardial infarction (MI) and non-fatal 
stroke. 
 We observed that although insulin treatment was indeed associated with weight gain, this 
did not translate to adverse CV outcomes and mortality in patients with T2D and so 
provides reassurance on the cardiovascular safety of insulin-induced weight gain in these 
patients. 
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Abstract: 
 
Background: This study aims to explore the association of insulin-induced weight (wt) gain 
on CV outcomes and mortality amongst patients with T2D following insulin initiation using 
real-world data 
Methods: A retrospective cohort study was performed in 18,814 adults with insulin-treated 
T2D derived from the UK Health Improvement Network (THIN) database. Based on the 
average weight change of 5kg, one year post-insulin initiation, patients were grouped into 5 
categories (>5kg wt loss; 1.0-5.0kg wt loss; no wt change; 1.0-5.0kg wt gain; and >5.0kg wt 
gain) and followed-up for 5 yrs. Cox proportional hazard models and Kaplan-Meier estimators 
were fitted to estimate the hazards of a three-point composite of non-fatal myocardial 
infarction, stroke and all-cause mortality between the categories. 
Results: The median age was 62.8 (IQR: 52.3–71.8) years, HbA1c: 8.6% (IQR: 7.4–9.8) and 
mean BMI: 31.8(6.5) kg/m2. The 5-year probability of survival differed significantly within the 
wt-change categories (log-rank test p-value=0.0005). A total of 1963 composite events 
occurred. Compared to the weight-neutral group, the risk of composite events was 31% greater 
in the >5kg wt-loss group (aHR: 1.31; 95%CI: 1.02, 1.68), the same in the 1.0-5.0kg wt-gain 
category; but non-significantly increased in the 1.0-5.0kg wt-loss (15%); and >5.0kg wt-gain 
(13%) categories respectively.  In the obese subgroup, this risk was 50% (aHR: 1.50, 95%CI: 
1.08 – 2.08) more in the >5kg weight-loss group, compared to the weight-neutral group. 
 
Conclusion: Insulin-induced weight-gain did not translate to adverse CV outcomes and 
mortality in patients with T2D. This data provides reassurance on the cardiovascular safety of 
insulin-induced wt gain in patients with T2D  
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Introduction: 
Insulin therapy commonly results in weight gain in patients with type 2 diabetes (T2D).[1] In 
the United Kingdom Prospective Diabetes Study (UKPDS), patients in the intensive 
intervention cohort gained in excess of 5 kg during the 10-year follow-up period, with most of 
this gain occurring in the first 12 months.[2] In routine clinical practice, however, we have 
previously shown that the effectiveness of insulin therapy to lower HbA1c levels however is 
variable and associated with patients’ baseline weight.[3,4] This is because insulin-induced 
weight gain results in an increase in the amount of insulin required to control hyperglycaemia 
[5,6], at the expense of further weight gain, possible poor treatment compliance and increased 
insulin resistance. 
Despite the well-recognised correlation between weight gain and cardiovascular (CV) disease, 
there is little direct evidence relating to the impact of insulin-induced weight-gain on CV 
outcomes.  However, there is compelling indirect evidence that weight-gain does adversely 
affect CV risk. In the Nurses’ Health Study, weight gain of >2kg following a diagnosis of 
diabetes was associated with a 16% increased risk of CV heart disease.[7]  The ACCORD study 
designed to investigate whether an aggressive therapeutic strategy to achieve tight glucose 
target (HbA1c <6.5%) would reduce CV events surprisingly resulted in an increased mortality 
in the intensively treated group.[8] The mean BMI of patients in the study was 32.2kg/m2 and 
weight-gain by more than 10kg occurred in 27.8% of the intensively treated patients compared 
with 14.1% in the standard therapy. While a causal relationship between weight gain and 
adverse CV outcomes cannot be assumed, retrospective studies have shown that people with 
diabetes who actively lose weight improve not only their risk profile [9–11] but also survival 
rate. The aim of the present study therefore was to explore the association of insulin-induced 
weight (wt) gain on CV outcomes and mortality in patients with T2D following insulin 
initiation using evidence from real-world data.
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Methods: 
Study Design and Data Source: 
A retrospective cohort study was conducted with data obtained from the UK Primary Care via 
The Health Improvement Network (THIN) database. This database hosts the UK computerised 
anonymised longitudinal Primary Care records which have data systematically entered in a 
non-interventional manner by Primary Care physicians. In addition, it contains details of over 
10.5 million patients (of this, 4.8 million are currently active) derived from 532 General 
Practices within the UK. It contains information on patients’ demography, lifestyle 
characteristics, diagnoses, hospital admissions, laboratory results, prescriptions, referrals, 
immunisations, clinical measures and Townsend deprivation scores. Several studies have 
validated and shown it to be demographically representative of the UK population in terms of 
demography, disease prevalence and mortality. [12,13] We have also used it previously to 
evaluate diabetes-related outcomes in routine clinical practice. [14,15,16] Ethical approval was 
obtained from the South-East Research Ethics Committee. 
Study Population: 
All adult T2D insulin users, aged 18 and above were eligible for inclusion. Furthermore, these 
patients must have initiated insulin therapy between January 2007 and 2014 irrespective of 
previous or concurrent use of other glucose-lowering therapies (GLTs). Patients with history 
of CV diseases prior to insulin initiation were excluded from the study. Additionally, to 
minimise the prevalent user bias, patients with diagnoses of CV diseases (non-fatal MI and 
stroke) on insulin initiation or up to 180 days after were also excluded; while patients with type 
1 diabetes were not eligible for inclusion in the study. Figure 1 is a flow chart illustrating how 
the study cohort was derived. 
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Exposure and Outcome: 
We defined the exposure as change in weight, one year post-insulin initiation. Change in weight 
was measured by the difference between the baseline weight (at insulin initiation) and the 
weight after one year, measured in kilogram. There was no consideration on the specific type 
or mode of administration of insulin. We classified the change in weight after one year of 
initiating insulin into five categories based on the average weight change of 5kg within this 
period as reported by previous studies. [2]   Change in weight was classified into the following 
categories: >5kg wt loss; 1.0-5.0kg wt loss; no wt change; 1.0-5.0kg wt gain; and >5.0kg wt 
gain. Participants were followed up for 5years to the earliest of the occurrence of any of the 
defined composite outcome, loss to follow-up (transfer out of practice),   discontinuation of 
insulin therapy, or at the end of the study after 5 years . 
The study outcome was time to a three-point composite of all-cause mortality, non-fatal 
myocardial infarction (MI) and non-fatal stroke. Appropriate READ CODES were used to 
identify and extract these outcomes from the THIN database.  
Covariates: 
Baseline variables were selected a priori based on clinical significance. These were extracted 
within the time period extending 90 days before and after initiation of insulin. These covariates 
included baseline demographic parameters as age, sex, socioeconomic deprivation and 
smoking status. In addition, clinical measures as body weight, body mass index (BMI) and 
blood pressure (systolic and diastolic); biochemical parameters as baseline HbA1c, creatinine 
level,  total cholesterol levels, low-density lipoprotein (LDL), high-density lipoprotein (HDL) 
and triglycerides were included. Other important covariates as the use of other medications as 
statins, aspirin, antihypertensive drugs, and oral antidiabetic drugs; comorbidities; the duration 
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of diabetes, duration of insulin use; and the duration of treatment of diabetes were also explored 
and included. 
Statistical Analyses: 
Baseline variables were summarised within these categories of weight-change using mean 
values and standard deviation (SD) for continuous variables; and frequencies (%) for 
categorical variables. The differences between these baseline categories were analysed using 
Pearson’s Chi square tests or linear regression and summarized in a table.  Missing data among 
the exposure variable (weight) and other baseline covariates in the dataset were generally 
accounted for using multiple imputations with the chained equation (MICE) model.  
The primary analysis was time to a three-point composite outcome of non-fatal MI, non-fatal 
stroke and all-cause mortality.  Crude and adjusted Kaplan–Meier estimates of survival 
functions were obtained for the categories of weight-change with log-rank test comparing the 
equality of the survival curves between them. From these survival functions, the absolute 
reduction in the probability of an event occurring within a 5-year follow-up was determined.  
We fitted a Cox proportional regression model to estimate the marginal hazard ratios and 
quantify the adjusted hazard of an event occurring in all the quintile groups compared to the 
third (no weight change) group. Covariates which had significant association in our univariate 
analysis at a p value ≤ 0.05 were included and adjusted for in the final model. Violations of the 
proportional hazards assumptions were confirmed through Schoenfeld residuals test.  
Subgroup/Sensitivity Analyses: 
Additional sensitivity analyses were carried out to evaluate the robustness of our data. We 
examined the assumption of no unmeasured covariate by examining if any unmeasured 
covariate would influence the measure of effect. Also, we compared results of the study 
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outcome between the datasets with missing data and the imputed data. This is to assess the 
reliability of these  outcomes and any possible impact any missing data might have on them. 
Additionally, the exposure was reclassified as quintiles of weight-change and the outcomes 
were compared with our results. Subgroup analyses were performed on patients with BMI > 
30kg/m2 to estimate the impact of weight changes on adverse composite outcomes in the obese 
population.  
Point estimates with 95% confidence intervals (CI) at the conventional statistical significance 
level of 0.05 were used in the regression models. All analyses were conducted using Stata 
software, version 14. [17] The study was reported using the STROBE criteria for reporting 
observational studies.
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Results: 
Cases and Total Follow up: 
A total of 18,814 adult T2D patients, identified in the UK Primary care electronic records via 
THIN database, fulfilled our inclusion criteria. In Figure 1, a flow diagram illustrates how this 
cohort was derived.  This population was distributed thus: >5kg wt loss (21.9%); 1.0-5.0kg wt 
loss (28.2%); no wt change (5.2%); 1.0-5.0kg wt gain (20.5%); and >5.0kg wt gain (24.3%). 
The mean follow up duration was 3.7±2.9 years which represents a total follow-up period of 
65,435.704 person-years.  
Patients’ Characteristics: 
The overall mean age was 61.5 (SD: 13.6) years with a mean HbA1c of 8.7% (SD: 1.8) and 
higher proportion (53.2%) of males. The 1.0 - 5.0kg group was younger, while the weight 
neutral group had lower HbA1c. The overall mean weight was 91.3kg but the group who lost 
more than 5kg had a greater weight of 96.6kg. Summarily, significant differences were 
observed between the categories in socio-economic status (p = 0.05), alcohol intake (p = 0.048) 
and use of lipid-lowering agents (p=0.0001). Table 1 summarises the baseline characteristics 
of the study cohort by the categories of change in weight one year after the initiation of insulin.  
The proportions of recorded data observed to be missing for weight were 15.8% and 36.5% at 
baseline and after one year were respectively. These were noted to be missing at random. 
Crude Event Rates: 
Although the probability of survival was similar (99%) between the weight categories at one 
year, there was a general decrease at five years in all the weight-change categories. This ranged 
from 83% in the group who lost > 5kg, to 88% in the weight neutral group (log-rank test p-
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value =0.0005). Figure 2 shows a Kaplan-Meier plot of survival probability for the composite 
outcomes within the weight-change categories  
Overall, there were 1,963 composite events of all-cause mortality, non-fatal stroke and non-
fatal acute MI; with a crude incidence rate of 30 per 1,000 person-years (95%CI: 28.8 – 31.5). 
These were distributed thus within the weight change categories: Those with >5kg weight loss: 
498 events (36 per 1000pyrs); 1 to 5kg weight loss: 544events (29 per 1000pyrs); no change in 
weight: 87 events (26 per 1000pyrs); 1 to 5kg weight gain: 360events (26 per 1000pyrs); and 
>5kg weight gain: 474 events (30 per 1000pyrs). These events are summarised in Table 2.  
 
Risk of Composite CV Outcomes: 
The Hazard of the three-point composite outcome of non-fatal AMI, non-fatal stroke and all-
cause mortality was compared to the no weight change group (Table 2). The unadjusted hazard 
for the composite outcome was 41% higher (HR: 1.41, 95%CI: 1.23 – 1.77) in patients who 
lost greater than 5kg weight year post-insulin initiation compared to the weigh-neutral group. 
However, this risk was 15%, 3% and 19% non-significantly higher in the 1.0 – 5.0kg weight 
loss; 1.0 - 5.0kg weight gain and >5.0kg weigh-gain groups respectively in the unadjusted 
model.. 
 Following adjustment for significant baseline variables as age, duration of diabetes, diastolic 
and systolic blood pressures, height, weight, albumin, glomerular filtration rate, gender, 
smoking status, alcohol status, lipid profile, socio-economic status (measured by Townsend 
deprivation scores), use of other glucose-lowering medications and antihypertensives; and 
other comorbidities (as heart failure and peripheral artery disease); the hazard slightly reduced 
to 31% (aHR: 1.31, 95%CI: 1.02 – 1.68) in patients who lost greater than 5kg compared to the 
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weight-neutral group. Similarly, the hazard was non-significantly reduced to 13% (95%CI: 
0.93 – 1.15) in those who gained > 5kg of weight but was the same (aHR: 1.15, 95%CI: 0.90 
– 1.47) in those who lost 1 to 5kg and unity (aHR: 1.00, 95%CI: 0.78 – 1.30) in those who 
gained 1 to 5kg, compared to the weight-neutral group.  
The proportional hazards assumptions of the cox-regression analysis were tested by adding by 
comparing the cumulative hazard plots groups on the exposure group, including an interaction 
term of the predictor and log time and also by using Schoenfeld residuals test. We observed no 
violations as both were found to be non-significant and satisfied the proportional hazard 
assumption.  
 
Sensitivity and Subgroup Analyses: 
Obese subgroup: In the obese (BMI of 30kg/m2 and above) population subgroup, 1201 
composite events occurred, giving a crude incidence rate of 29/1,000 person-years (95%CI: 28 
- 31). The distribution of the events and their incidence rates by the weight change groups are 
shown in Table 2. Compared to the weight-neutral group, the adjusted risk of composite CV 
risk and all-cause mortality event was 50% (aHR: 1.50, 95%CI: 1.08 – 2.08) more in the obese 
population group who lost greater than 5kg at one year post-insulin initiation compared to the 
weight-neutral group. Similarly, a non-significant  increase of 27%, 14% and 29% in this risk 
was, however, reported in the 1 to 5kg weight-loss, 1 to 5kg weight-gain and >5kg weight-gain 
groups as shown in Table 2. 
Risk of mortality, non-fatal MI and non-fatal stroke: The events, and hazards of the 
components of the three-point composite event are shown in Table 3. Patients who lost greater 
than 5 kg one-year post-insulin initiation showed increased risk of mortality of 27% (95%CI: 
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1.01 – 1.89, but no statistically significant difference in risk was found for non-fatal MI 
although it showed a 5-fold increased risk (aHR: 5.06, 95%CI:0.68 – 37.67).Also, the risk of 
non-fatal stroke was non-significantly increased by 15% (aHR: 1.15, 95%CI: 0.77 – 1.71) 
compared to the no weight-neutral category. Summarily, other weight categories in all the 
composite components showed non-significant greater risks compared to the weight-neutral 
group as shown in Table 3. 
Sensitivity analyses comparing the hazards of the composite events between the weight-change 
categories ranked in quintiles, showed similar pattern in the risk of the three-point composite 
event. Similarly, we obtained similar results and trend in risk of the composite outcome and 
individual components of the 3-point composite outcome when we compared the incomplete 
and imputed datasets. This affirmed that the imputation robustly addressed the missing data.
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Discussion: 
This observational study, derived from a large longitudinal real world data provides 
reassurance that weight-gain associated with insulin treatment is not associated with adverse 
CV outcomes. Conversely, patients who demonstrated significant weight loss with insulin 
treatment appear to have a more adverse CV outcomes compared to that observed in patients 
who maintained or increase their body weight. This observation persists when sub-analysed for 
patients who are obese (BMI 30kg/m2) at baseline and when adjusted for various confounding 
factors.  
Our findings  are further supported by consistency of the outcomes in patients from the entire 
cohort, and in the subgroup and sensitivity analyses. The level of HbA1c and CV risk profile 
(e.g. lipid, blood pressure) were clinically similar across all weight change categories. 
Although we did not assess the impact of HbA1c change and weight change across different 
baseline weight categories, a previous study using a US-based electronic medical record 
reported a reduction in HbA1c was associated with progressively less weight gain as baseline 
BMI rose. [18] The inference from that study that the lesser weight gain seen in obese patients 
was due to the use of less intensive insulin therapy may also apply to this cohort. 
Although it seems logical that weight gained in people with diabetes, a disease with a high 
incidence of CV risk, would increase CV events, there is in fact little direct evidence to support 
this. Robust large scale clinical trials such as UKPDS [2], ADVANCE [19] and ACCORD [8] 
study did not stratify their CV outcomes by weight-loss or weight-gain, for any given level of 
glycaemic control. Even though the ACCORD study reported excess mortality (and more 
weight gain) in the intensively treated group, a causal link cannot be inferred. Of note however, 
was in a post hoc analysis of that same study, patients who were inadequately controlled at 
baseline and received intensive glucose lowering strategy but still had suboptimal glucose 
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control (HbA1c >7% (>53 mmol/mol)) experienced higher mortality rate [20]. Thus, patient-
factors associated with persistently high HbA1c, despite intensive treatment, appear to be the 
most important determinant of increased mortality risks. To this end, insulin-induced weight 
gain in our study was seen to be associated with a reduction in HbA1c, while those who lost 
weight were associated with a deterioration or unchanged HbA1c levels (Figure 3).  
Three possible explanations could be inferred from this observation. Firstly, a rise in HbA1c 
levels may dilute any favourable impact of weight reduction and lead to an increase in CV 
events. In support of this, there is evidence that intensive control of blood glucose levels in 
patients with T2D reduces the long-term risk of adverse CV events.[21,22] These benefits may 
take many years to become apparent but in view of the association between patients’ HbA1c 
level, and risk of developing long-term vascular complications, current clinical guidelines 
recommend aggressive treatment escalations among patients with T2D to achieve low HbA1c 
targets.[23,24,25] Conversely, patients may however find the demands of intensive glycaemic 
control difficult to manage resulting in psychological stress, frustration and non-adherence 
especially if hypoglycaemia occurs.[26] A second, perhaps more likely explanation is the 
presence of other comorbidities (e.g. cancers, gastrointestinal disorders, other 
endocrine/metabolic disorders, etc.) which are associated with weight loss in the group who 
lost weight in excess of 5kg. These could have possibly driven the adverse outcomes seen in 
this group. Thirdly, insulin-induce weight gain could suggest patients’ compliance to insulin 
treatment intensification and thus a surrogate marker of compliance to holistic care and 
treatment. Nevertheless, we contend that there is indirect evidence that failure to achieve 
HbA1c reduction, irrespective of the evidence for this, should be used as a trigger to intensify 
cardiovascular risk reduction strategies.  
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Our study findings are in keeping with the outcome of another real world study in Australia 
which showed that insulin-induced weight-gain was not associated with adverse changes in 
cardiovascular risk factors after one year of insulin initiation. [27] Conversely,  our data are in 
contrast to the findings in type 1 diabetes. In a sub-analysis of the DCCT study, Purnell et al. 
stratified data from the intensively treated DCCT cohort by quartiles of weight gain. [28] 
Comparing the first quartile (where BMI remained stable) with the fourth (where BMI 
increased by 7 kg/m2), after a mean follow-up of 6.1 years, patients in the fourth quartile were 
associated with significant negative changes in all CV risk parameters. While a causal 
relationship between weight gain and adverse CV outcomes again cannot be assumed, other 
studies have reported that people with diabetes who actively lose weight improve not only their 
risk profile but also their longevity.[29,30] These studies however did not focus on patients 
with T2D receiving insulin therapy. In this context, while weight-gain has to be viewed as an 
undesirable side effect of insulin therapy, it appears to be associated with adverse CV outcome 
in patients with type 1 diabetes.  
Our analyses were subject to a number of limitations that are inherent to observational studies. 
Firstly, we cannot be certain that the patients were fully compliant with their medication. Also, 
some factors like lifestyle and dietary intervention and records of comorbidities as cancers and 
metabolic disorders (which were not so robustly included in our data) may influence our 
findings. We were also not able to obtain the longitudinal insulin doses, an important predictor 
of insulin-induced weight gain. [31,32] Since our aim was to look at status of weight-change 
due to insulin initiation per se on CV outcomes, we would argue that this should not influence 
the robustness of our findings.  Although we could not account for potential residual 
confounders such as compliance, indications for intensification treatments, markers of β-cell 
deterioration and frequency of hypoglycaemia, we were able to account for differences in the 
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observed covariates and used robust analytical techniques to control confounding that may bias 
the results of the estimated treatment effects.  
In conclusion, we observed that in the group which experienced weight gain following insulin 
treatment, insulin-induced weight gain+ was however not associated with adverse CV 
outcomes as indirectly suggested in previous clinical trials.  These findings should provide 
important reassurance among patients with T2DM who gained weight following insulin 
treatment in routine clinical practice
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Legend: 
 
 
Figure 1 – Flow diagram illustrating the selection of the study cohort 
 
Figure 2 – Kaplan-Meier Curve showing the probability of survival between the weight-
change categories within the follow-up period. Log-rank test p-value = 0.0005. 
 
Figure 3 – Relationship between change in weight and glycaemic control.  
This figure illustrates the association between glycaemic control (measured by the difference 
between baseline HbA1c and level after one year of insulin initiation) and change in weight 
after one year of initiation of insulin in naïve insulin users. For a unit increase in weight at one 
year post-insulin initiation, there was a marginal but significant reduction in HbA1c (r: - 
0.005%, 95%CI: -0.007 to -0.002%; p-value: 0.001). 
 
 
 
Table 1 - Baseline characteristics of study cohort by categories of weight change. 
 
Table 2 – Events, Incidence Rate and Hazards of Composite Outcome by Weight-Change 
Categories 
 
Table 3 - Events, Incidence Rate and Hazards of the Components of the Three-point Composite 
Outcome by Weight-Change Categories
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Table 1 
Tables 
Table 1:  
Weight Change 
Lost > 5kg  Lost 1.0 to 5.0kg  No Change Gained 1.0 to 5.0kg Gained > 5.0kg  Total 
(n = 4116) (n = 5311) (n = 970) (n =3852) (n = 4565) (n = 18,814) 
Demographics       
Age (yrs). Mean (SD) 61.8 (14.0) 61.3 (13.5) 61.8 (13.6) 60.8 (13.6) 62.1 (13.5) 61.5 (13.6) 
Gender. No. (%)       
                  Male 2150 (52) 2807 (53) 503 (52) 2046 (53) 2508 (55) 10,014 (53.2) 
                  Female 1966 (48) 2504 (47) 467 (48) 1806 (47) 2057 (45) 8800 (46.8) 
Smoking Status. No (%)       
        Non-smoker 2006 (49) 2607 (49) 464 (48) 1893 (49) 2208 (48) 9178 (48.8) 
        Ex-smoker 1497 (36) 1924 (36) 355 (37) 1402 (36) 1754 (38) 6,932 (36.8) 
        Current 613 (15) 780 (15) 151 (16) 557 (14) 603 (13) 2704 (14.4) 
Alcohol Status. No (%)       
       Never 1635 (40) 1960 (37) 338 (35) 1401 (36) 1725 (38) 1202 (6.4) 
       Ex-drinker 249 (6) 328 (6) 70 (7) 253 (7) 302 (7) 7059 (32.5) 
       Current 2232 (54) 3023 (57) 562 (58) 2198 (57) 2538 (56) 10,553 (56.1) 
Deprivation. No (%)       
         Least deprived 814 (21) 1042 (21) 204 (22) 732 (20) 888 (20) 3680 (19.7) 
         Second quintile 784 (20) 1016 (20) 187 (20) 751 (20) 863 (20) 3601 (19.1) 
         Third quintile 846 (22) 1088 (21) 193 (21) 740 (20) 963 (22) 3830 (20.4) 
         Fourth quintile 822 (21) 1116 (22) 202 (22) 818 (22) 937 (21) 3895 (20.7) 
         Most deprived 655 (17) 816 (16) 140 (15) 634 (17) 711 (16) 2956 (16.5) 
       
Clinical Parameters. Mean (SD)      
    HbA1c (%) 8.6 (1.8) 8.7 (1.8) 8.6 (1.8) 8.7 (1.8) 8.7 (1.9) 8.7 (1.8) 
    BMI (kg/m2) 34.7 (6.8) 32.9 (6.6) 32.3 (6.4) 31.9 (6.7) 30.6 (6.8) 32.5 (6.9) 
    Diabetes duration (yrs) 4.5 (4.8) 4.1 (4.9) 4.3 (4.6) 4.1 (4.8) 4.6 (5.1) 4.3 (4.9) 
    Time on insulin (yrs) 4.1 (6.2) 3.8 (6.4) 4.3 (6.4) 3.7 (6.2) 4.0 (6.6) 3.9 (6.4) 
    Height (m) 1.7 (0.1) 1.7 (0.1) 1.7 (0.1) 1.7 (0.1) 1.7 (0.1) 1.7 (0.1) 
    Weight (kg) 96.6 (18.3) 92.1 (18.2) 90.3 (17.8) 89.8 (18.4) 87.0 (18.8) 91.3 (18.7) 
    DBP (mmHg) 76.2 (10.8) 75.8 (10.9) 75.9 (10.7) 75.8 (10.9) 76.1 (10.8) 76.0 (10.8) 
    SBP (mmHg) 138.7 (23.1) 136.6 (22.9) 135.7 (21.6) 135.7 (22.7) 134.5 (23.5) 136.3 (23.0) 
    Albumin (g/L) 4.0 (0.4) 4.1 (0.4) 4.1 (0.4) 4.1 (0.4) 4.1 (0.4) 4.0 (0.4) 
    ACR (mg/mol) 5.8 (8.5) 5.8 (8.6) 6.1 (8.4) 5.7 (8.4) 5.8 (8.4) 5.8 (8.5) 
    eGFR (mls/min/1.73m2) 61.7 (21.3) 63.0 (21.2) 62.4 (21.4) 63.6 (20.8) 63.6 (21.3) 62.9 (21.2) 
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    TC. (mmol/L) 4.6 (1.3) 4.5 (1.3) 4.5 (1.2) 4.5 (1.3) 4.5 (1.3) 4.5 (1.3) 
    Triglyceride (mmol/L) 2.1 (1.3) 2.1 (1.2) 2.0 (1.1) 2.0 (1.2) 2.1 (1.2) 2.0 (1.2) 
    LDL (mmol/L) 2.4 (1.1) 2.4 (1.1) 2.3 (1.0) 2.4 (1.1) 2.3 (1.1) 2.4 (1.1) 
    HDL (mmol/L) 1.2 (0.4) 1.2 (0.4) 1.2 (0.4) 1.2 (0.5) 1.2 (0.5) 1.2 (0.4) 
BMI Categories       
            Normal 319 (8) 580 (11) 128 (13) 569 (15) 948 (21) 2544 (13.5) 
             Overweight 717 (17) 1296 (24) 241 (25) 990 (26) 1233 (27) 4477 (23.8) 
             Obese 3080 (75) 3435 (65) 601 (62) 2293 (60) 2384 (52) 11,793 (62.7) 
       
Use of Medications       
            Aspirin 3940 (98) 5079 (97) 923 (99) 3710 (99) 4395 (98) 18047 (98) 
            LLT 3541 (90) 4621 (91) 840 (91) 3368 (91) 3972 (90) 16342 (90.5) 
           Antihypertensives 3565 (90) 4630 (91) 844 (91) 3370 (91) 4022 (91) 10830 (87.7) 
       
Comorbidities       
           Hypoglycaemia 725 (18) 902 (17) 177 (18) 686 (18) 790 (17) 3280 (17) 
           Heart Failure 568 (14) 712 (13) 138 (14) 518 (13) 663 (15) 2599 (13.9) 
           PAD 522 (13) 688 (13) 130 (13) 511 (13) 660 (14) 2511 (13.4) 
           Other CHD 1226 (30) 1615 (30) 276 (28) 1144 (30) 1420 (31) 5681 (30.2) 
       
Diabetes duration is time from first diagnosis of diabetes to date of intensification with insulin (index date). 
Comorbidities: other recorded medical disorders. 
ACR, albumin creatinine ratio; BMI, body mass index; CHD, coronary heart disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, Haemoglobin A1c; HDL, high-density 
lipoprotein; INS, insulin; LDL, low-density lipoprotein; LLT, lipid-lowering therapy; PAD, peripheral arterial disease; SBP, systolic blood pressure; TC, total cholesterol. 
DMRR-17-RES-024 
 
 
 
 
 
 
 
Table 2: 
 
Weight Change 
Lost > 5kg  
Lost 1.0 to 
5.0kg  
No Change 
Gained 1.0 
to 5.0kg 
Gained > 
5.0kg  
Total 
(n = 4116) (n = 5311) (n = 970) (n =3852) (n = 4565) (n = 18,814) 
Study Population       
Composite Outcomea 498 544 87 360 474 1963 
Incidence rate (per 1000pyrs)  35.7 29.4 25.5 26.3 30.3 30.1 
(95% CI) (32.7 – 39.0) (27.0 – 32.0) (20.7 – 31.5) (23.7 – 29.2) (27.7 – 33.1) (28.8 – 31.5) 
       
Adjusted Hazard Ratiob  1.31 1.15 1 (ref) 1.00 1.13 - 
(95% CI) (1.02 – 1.68) (0.90 – 1.47) - (0.78 – 1.30) (0.93 – 1.15) - 
p-value 0.032 0.263 - 0.975 0.344 - 
       
Obese subgroup (BMI ≥ 30kg/m2)     
       
Composite Outcomea 362 335 49 209 246 1201 
Incidence rate (per 1000pyrs)  34.5 27.7 23.3 25.5 29.8 29.2 
(95% CI) (31.2 – 38.3) (24.9 – 30.9) (17.6 – 30.8) (22.2 – 29.1) (26.3 – 33.8) (26.3 – 33.8) 
       
Adjusted Hazard Ratiob  1.50 1.27 1 (ref) 1.14 1.29 - 
(95% CI) (1.80 – 2.08) (0.91– 1.76) - (0.81 – 1.60) (0.92 – 1.81) - 
p-value 0.014 0.159 - 0.455 0.136 - 
       
a Composite outcome includes all-cause mortality,  non-fatal acute myocardial infarction (AMI) and non-fatal stroke. 
b Adjusted for age, diabetes duration diastolic and systolic blood pressure, height, weight, albumin, glomerular filtration rate, gender, smoking 
status, alcohol status, lipid profile, Townsend Deprivation score, number of glucose-lowering therapies, Lipid-lowering therapies, 
antihypertensives, heart failure and peripheral artery disease. 
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Table 3 
 
 
      Weight Change 
Lost > 5kg  
Lost 1.0 to 
5.0kg  
No Change 
Gained 1.0 to 
5.0kg 
Gained > 5.0kg  Total 
(n = 4116) (n = 5311) (n = 970) (n =3852) (n = 4565) (n = 18,814) 
Mortality       
Total Events 312 320 51 208 260 1151 
Incidence rate (per 1000)  19.9 15.3 13.2 13.5 14.6 15.6 
(95% CI) (17.8 – 22.2) (13.7 – 17.1) (10.0 – 17.4) (11.8 – 15.5) (12.9 – 16.5) (14.8 – 16.6) 
       
Adjusted Hazard Ratioa  1.37 1.14 1 (ref) 0.99 1.01 - 
(95% CI) (1.01 – 1.89) (0.83 – 1.57) - (0.71 – 1.38) (0.72 – 1.39) - 
p-value 0.051 0.421 - 0.947 0.986 - 
       
Non-fatal Myocardial Infarction      
Total Events 25 25 2 28 36 116 
Incidence rate (per 1000)  1.6 1.2 0.5 1.9 2.1 1.6 
(95% CI) (1.1 – 2.4) (0.8 – 1.8) (0.1 – 2.1) (1.3 – 2.7) (1.5 – 2.9) (1.3 – 1.9) 
       
Adjusted Hazard Ratioa  5.06 4.26 1 (ref) 5.42 7.71 - 
(95% CI) (0.68 – 37.67) (0.58 – 31.57) - (0.73 – 40.33) (1.06 – 56.34) - 
p-value 0.113 0.156 - 0.099 0.044 - 
       
Non-fatal Stroke      
Total Events 161 199 34 124 178 696 
Incidence rate (per 1000)  11.3 10.4 9.7 8.8 11.0 10.3 
(95% CI) (9.6 – 13.1) (9.1 – 12.0) (6.9 – 13.6) (7.4 – 10.5) (9.5 – 12.7) (9.6 – 10.3) 
       
Adjusted Hazard Ratioa  1.15 1.10 1 (ref) 0.95 1.12 - 
(95% CI) (0.77 – 1.71) (0.74 – 1.63) - (0.63 – 1.43) (0.75 – 1.65) - 
p-value 0.509 0.627 - 0.810 0.579 - 
aAdjusted for age, diabetes duration diastolic and systolic blood pressure, height, weight, albumin, glomerular filtration rate, gender, smoking 
status, alcohol status, lipid profile, Townsend Deprivation score, number of glucose-lowering therapies, Lipid-lowering therapies, 
antihypertensives, heart failure and peripheral artery disease. 
 
 
 
 
